Biogen stocks up on Sage's brain drugs in $3B deal

Biogen stocks up on Sage's brain drugs in $3B deal

Source: 
BioPharma Dive
snippet: 

Biogen, the world's largest biotech focused on brain diseases, is adding two experimental medicines to its arsenal through a collaboration with a fellow Cambridge, Massachusetts-based drugmaker, Sage Therapeutics, that could be worth more than $3 billion.